Immunotherapy in the treatment of non-small cell lung cancer.

Immunotherapy with check-point inhibitors has demonstrated remarkable therapeutic benefits in many oncological diagnoses, including non-small cell lung cancer (NSCLC). Based on the data from clinical trials, it has become an important part of the NSCLC treatment algorithm. Treatment with programmed cell death protein 1 / programmed death-ligand 1 inhibitors can be indicated in various ways: as monotherapy or combination of immunotherapy with cytotox--ic T-lymphocyte antigen 4 inhibitors or in combination with other treatment modalities - chemotherapy, antiangiogenic therapy and radiotherapy. Regarding new spectrum of immune-related side effects, which require quick diagnosis and treatment, there is great urge to identify immunotherapy predictive biomarkers.